Ascites
Ascites
References
- The Serum-Ascites Albumin Gradient Is Superior to the Exudate-Transudate Concept in the Differential Diagnosis of Ascites — Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. Ann Intern Med 1992;117(3):215-220
- Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by AASLD — American Association for the Study of Liver Diseases (Biggins SW, Angeli P, Garcia-Tsao G, Ginès P, Ling SC, Nadim MK, Wong F, Kim WR). Hepatology 2021;74(2):1014-1048
- Systematic review: tuberculous peritonitis — presenting features, diagnostic strategies and treatment — Sanai FM, Bzeizi KI. Aliment Pharmacol Ther 2005;22(8):685-700
- Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures — Sangisetty SL, Miner TJ. World J Gastrointest Surg 2012;4(4):87-95
- 2015 ESC Guidelines for the diagnosis and management of pericardial diseases — European Society of Cardiology (Adler Y, Charron P, Imazio M, et al.). Eur Heart J 2015;36(42):2921-2964
- KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases — Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. Kidney Int 2021;100(4S):S1-S276
Clinical Snapshot
Ascites is the pathologic accumulation of fluid within the peritoneal cavity. It is not a diagnosis in itself but a sign with a wide differential, and the mechanism driving it — not the volume of fluid or how it looks on exam — is what determines correct management.
Cirrhosis with portal hypertension causes the large majority of all ascites, and its ambulatory management (sodium restriction, spironolactone/furosemide titration, large-volume paracentesis, refractory-ascites recognition, spontaneous bacterial peritonitis prophylaxis) is the subject of the dedicated Cirrhosis chapter — that content is deliberately not duplicated here.
This chapter instead focuses on the question that has to be answered before that ladder is appropriate to use at all: is this actually cirrhotic ascites? A meaningful minority of ascites is driven by a different mechanism entirely — malignancy/peritoneal carcinomatosis, cardiac or constrictive disease, tuberculous peritonitis, nephrotic syndrome, or pancreatic/biliary leakage — each of which is managed completely differently, and several of which respond poorly or not at all to the cirrhotic diuretic ladder. The serum-ascites albumin gradient (SAAG) is the internationally standard first step in telling these apart: a single subtraction (serum albumin minus ascitic fluid albumin, drawn the same day) that classifies ascites as portal-hypertensive (SAAG ≥ 11 g/L) or non-portal-hypertensive (SAAG < 11 g/L) with roughly 97% accuracy in the original validation study — a substantially better discriminator than the older exudate/transudate concept it replaced.[1]
The organizing principle of this chapter, restated throughout: every new-onset ascites gets a diagnostic paracentesis and a SAAG, the result routes the patient down one of several distinct management pathways, and only one of those pathways — confirmed cirrhosis — leads to the ladder described in the Cirrhosis chapter.
Recognize the Condition
Physical findings
None of the classic bedside signs of ascites is reliable in isolation, and none of them distinguishes one cause from another — physical examination establishes that ascites is present, not why.
| Finding | Description |
|---|---|
| Flank bulging / fullness | Symmetric distension of the flanks with the patient supine; the most sensitive single sign, though nonspecific |
| Shifting dullness | Percussion dullness that migrates from the dependent flank as the patient rolls onto the opposite side |
| Fluid wave | A palpable impulse transmitted across the abdomen when the opposite flank is tapped; requires roughly 1-1.5 L or more of fluid and an assistant to dampen transmission through the abdominal wall |
| Umbilical eversion or new umbilical/inguinal hernia | From sustained intra-abdominal pressure; more common with long-standing, large-volume ascites |
Physical exam alone is estimated to miss ascites below roughly 1500 mL and performs inconsistently even above that threshold — abdominal ultrasound is far more sensitive (detecting as little as 100 mL) and should be used liberally, both to confirm ascites is genuinely present and to guide a safe diagnostic tap (see Assessment & Diagnosis).
History and exam clues that point toward a specific cause
These clues raise or lower suspicion for a given etiology — they do not replace the SAAG-based work-up, but they should shape which additional ascitic-fluid studies are ordered on the same tap rather than requiring a second procedure later.
| Clue | Etiology it raises |
|---|---|
| Known or recently diagnosed malignancy (ovarian, gastric, colorectal, pancreatic, breast, or primary peritoneal mesothelioma); rapid-onset, painful ascites; a palpable abdominal or pelvic mass | Peritoneal carcinomatosis / malignant ascites |
| Elevated jugular venous pressure, peripheral edema out of proportion to ascites, an S3 gallop, or a history of prior cardiac surgery/mediastinal radiation/recurrent pericarditis | Cardiac ascites, or constrictive pericarditis specifically |
| Immigration from or travel to a TB-endemic region, HIV infection or other immunosuppression, low-grade fever, night sweats, and unintentional weight loss | Tuberculous peritonitis |
| Marked peripheral and periorbital edema, frothy urine, and normal liver enzymes/imaging | Nephrotic-syndrome ascites |
| Known chronic pancreatitis or heavy alcohol use, recent pancreatic trauma or surgery, epigastric pain radiating to the back | Pancreatic (or biliary) ascites |
| Known cirrhosis with the usual stigmata (spider angiomata, palmar erythema, splenomegaly) — see the Cirrhosis chapter for the full differential of these findings | Cirrhotic ascites — by far the most common single cause overall |
Risk Factors
By etiology
- Malignancy / peritoneal carcinomatosis — ovarian, gastric, colorectal, pancreatic, and breast cancer are the most common primary sources; primary peritoneal mesothelioma is rarer but should be considered, especially with an asbestos exposure history.
- Cardiac / constrictive disease — heart failure with reduced or preserved ejection fraction, restrictive cardiomyopathy, and constrictive pericarditis (risk factors: prior cardiac surgery, mediastinal radiation, recurrent or tuberculous pericarditis, chronic renal failure).
- Budd-Chiari syndrome (hepatic venous outflow obstruction) — an underlying myeloproliferative neoplasm or other prothrombotic/hypercoagulable disorder, oral contraceptive use, pregnancy, and, in some regions, hepatic venous webs.
- Nephrotic syndrome — diabetic nephropathy, minimal change disease, membranous nephropathy, focal segmental glomerulosclerosis, amyloidosis, and lupus nephritis are the most common underlying glomerular diseases.
- Tuberculous peritonitis — birth, residence, or travel in a TB-endemic region, HIV infection or other immunosuppression (including biologic/immunosuppressive therapy), peritoneal dialysis, and a prior history of tuberculosis.
- Pancreatic / biliary ascites — chronic pancreatitis, heavy alcohol use, recent pancreatic trauma, surgery, or endoscopic instrumentation, and an untreated or unrecognized pancreatic pseudocyst.
- Cirrhosis — remains the single most common underlying cause of ascites overall by a wide margin; see the Cirrhosis chapter for its full risk-factor list (alcohol, MASLD/MASH, viral hepatitis, autoimmune and cholestatic liver disease, and others).
Red Flags & Refer
Escalate urgently for any of the following:
- Fever, abdominal pain or tenderness, or otherwise-unexplained worsening in a patient with ascites of any cause — this is the presentation of spontaneous bacterial peritonitis (SBP) or secondary bacterial peritonitis; SBP can complicate low-protein ascites regardless of underlying etiology, not only cirrhosis. Work it up and manage it per the Cirrhosis chapter's SBP content rather than repeating that pathway here — the diagnostic threshold (a low threshold for a repeat diagnostic tap) and the ascitic neutrophil-count criterion apply the same way whatever the underlying cause.[2]
- Severe, acute-onset abdominal pain with peritoneal signs — consider secondary peritonitis from a perforated viscus; this is a surgical emergency, not an ambulatory work-up.
- Tense ascites causing respiratory compromise or severe discomfort — arrange urgent therapeutic paracentesis regardless of the eventual etiology.
- Hemorrhagic ascitic fluid obtained on a non-traumatic tap — raises malignancy or tuberculous peritonitis; expedite cytology, culture, and ADA testing rather than treating it as an incidental finding.
- New ascites in a patient with a known cancer diagnosis — refer to oncology promptly rather than assuming a benign or unrelated cause.
- Rapidly worsening renal function in a patient with ascites of any cause — evaluate urgently; the cause can be intravascular depletion from nephrotic-range proteinuria, over-diuresis, or, in a cirrhotic patient, hepatorenal syndrome (see the Cirrhosis chapter for that specific work-up).
- Any new-onset ascites without an already-established cause — refer for full diagnostic work-up (see Assessment & Diagnosis) rather than presuming a cirrhotic etiology and starting the cirrhotic ladder without a diagnostic tap.
Assessment & Diagnosis
Diagnostic paracentesis comes first
Perform a diagnostic paracentesis, ideally ultrasound-guided, in essentially every patient with new-onset ascites at first presentation — and again for any unexplained change in a previously stable, already-characterized ascites. Routine correction of mild coagulopathy is not required beforehand; withholding a diagnostic tap to "correct" an elevated INR or a mildly low platelet count delays a result that frequently changes management, for a bleeding risk that is low in experienced hands.[2]
The serum-ascites albumin gradient (SAAG)
SAAG = serum albumin − ascitic fluid albumin, with both drawn on the same day. A gradient of ≥ 11 g/L (1.1 g/dL) indicates a portal-hypertensive mechanism; a gradient < 11 g/L (1.1 g/dL) indicates a non-portal-hypertensive mechanism. This single measurement is approximately 97% accurate for that broad classification — a materially better discriminator than the older total-protein-based exudate/transudate concept it has replaced.[1]
| SAAG ≥ 11 g/L (1.1 g/dL) — portal hypertensive | SAAG < 11 g/L (1.1 g/dL) — non-portal-hypertensive |
|---|---|
| Cirrhosis — by far the most common cause in this category; see the Cirrhosis chapter for the full treatment ladder | Peritoneal carcinomatosis / malignant ascites |
| Cardiac ascites (heart failure, constrictive pericarditis, restrictive cardiomyopathy) | Tuberculous peritonitis |
| Budd-Chiari syndrome / hepatic venous outflow obstruction | Pancreatic or biliary ascites |
| Portal or splenic vein thrombosis | Nephrotic syndrome |
| Massive hepatic metastatic replacement | Serositis from a connective tissue disease (e.g., lupus peritonitis) |
Total protein as a secondary differentiator
Once the SAAG establishes the broad category, ascitic total protein narrows it further:
- Within SAAG ≥ 11 g/L: total protein below 25 g/L (2.5 g/dL) is typical of cirrhosis; total protein at or above 25 g/L (2.5 g/dL) is atypical for straightforward cirrhosis and should prompt evaluation for a cardiac cause or Budd-Chiari syndrome instead (see Choose Initial Treatment).[2]
- Within SAAG < 11 g/L: the pattern of protein, cell count, and specific fluid markers points further — lymphocyte-predominant fluid with an elevated adenosine deaminase (ADA) suggests tuberculous peritonitis[3]; positive cytology (with variably elevated protein) confirms malignancy[4]; a markedly elevated ascitic amylase (typically several times the upper limit of serum amylase) indicates pancreatic ascites; and nephrotic-range proteinuria with a low serum albumin from urinary protein loss (rather than from reduced hepatic synthesis) points to nephrotic syndrome.
Which ascitic fluid studies to order
| Send on every tap | Add based on clinical suspicion |
|---|---|
| Cell count with differential (an absolute neutrophil count ≥ 250 cells/mm³ defines SBP — see Red Flags & Refer and the Cirrhosis chapter) | Culture — inoculate blood culture bottles at the bedside for the best yield |
| Albumin (paired with same-day serum albumin to calculate SAAG) | Cytology — malignancy |
| Total protein | Amylase — pancreatic/biliary ascites |
| Adenosine deaminase and AFB smear/culture — tuberculous peritonitis | |
| Triglycerides — chylous ascites | |
| Glucose and LDH — helps distinguish SBP from secondary (surgical) bacterial peritonitis when the latter is suspected |
Supporting labs and imaging
- Same-day serum albumin — required to calculate SAAG; without it the ascitic albumin result cannot be interpreted.
- BNP or NT-proBNP and transthoracic echocardiography when a cardiac cause is suspected or when total protein is atypically high for cirrhosis (see above).
- Contrast-enhanced CT of the abdomen and pelvis for malignancy staging, or to identify peritoneal caking, omental thickening, or lymphadenopathy suggestive of carcinomatosis or tuberculous peritonitis (imaging alone cannot reliably distinguish the two — fluid/tissue confirmation is still needed).
- Urinalysis with quantification of proteinuria whenever nephrotic syndrome is a consideration.
- HIV testing and an interferon-gamma release assay or tuberculin skin test when tuberculous peritonitis is suspected, recognizing that ascitic ADA and AFB studies are more diagnostically useful than a blood-based test alone.
Mixed and indeterminate pictures
A patient can have more than one concurrent driver of ascites — most importantly, a patient with known cirrhosis who develops a second, superimposed process such as peritoneal carcinomatosis. This can produce an indeterminate or falsely reassuring SAAG/total-protein pattern. A change in a previously stable cirrhotic patient's ascites — faster reaccumulation, new systemic symptoms, or bloody fluid — should prompt a repeat paracentesis with cytology rather than an assumption that the known cause has simply progressed (see Treatment Failure / Next Step).
Treatment Targets
- Identify the specific underlying cause through the SAAG-directed diagnostic work-up before committing to a management plan.
- Relieve symptomatic fluid accumulation using the modality actually proven effective for that specific cause — not a default diuretic trial applied to every etiology alike.
- Treat the underlying disease process driving fluid formation (optimize heart failure therapy, treat the malignancy, complete antituberculous therapy, immunosuppress the glomerular disease) as the durable solution, rather than relying on diuretics or paracentesis alone indefinitely.
- Avoid an empiric diuretic trial in etiologies known to respond poorly — most importantly isolated peritoneal carcinomatosis — so that the therapy that actually helps (therapeutic paracentesis, an indwelling catheter, or cause-directed treatment) is not delayed.
- Detect and manage secondary infection (spontaneous bacterial peritonitis) promptly regardless of the underlying cause.
- For confirmed cirrhotic ascites specifically, the detailed targets (sodium-restriction level, weight-loss pace, refractory-ascites definitions, SBP-prophylaxis criteria) are set out in the Cirrhosis chapter — this chapter's targets stop at getting the diagnosis right and apply to the non-cirrhotic causes.
Choose Initial Treatment
Management branches by SAAG category
Portal hypertensive (SAAG ≥ 11 g/L)
Cirrhosis (most common) → the Cirrhosis chapter's ladder. Cardiac/constrictive disease and Budd-Chiari → this chapter, below.
Non-portal-hypertensive (SAAG < 11 g/L)
Malignant ascites, tuberculous peritonitis, nephrotic-syndrome ascites, and pancreatic ascites — each managed by treating the specific driver, not a generic diuretic ladder.
Once cirrhosis is confirmed as the driver (SAAG ≥ 11 g/L, total protein below 25 g/L, and a compatible clinical/imaging picture), move directly to the dedicated ladder in the Cirrhosis chapter — sodium restriction, the 100:40 spironolactone:furosemide titration, large-volume paracentesis thresholds, refractory-ascites definitions, and spontaneous bacterial peritonitis prophylaxis criteria are covered there in full and are not repeated here.
When SAAG is ≥ 11 g/L but total protein is at or above 25 g/L (2.5 g/dL) — atypical for straightforward cirrhosis — reconsider a cardiac cause or Budd-Chiari syndrome before assuming cirrhosis and starting that ladder (see Assessment & Diagnosis and the directive below).
First-line diuresis with a loop diuretic (furosemide), adding spironolactone if response is inadequate, controls most cardiac ascites — but diuretics are adjunctive, not definitive. Durable control requires treating the underlying cardiac process; see the Heart Failure chapter for the full guideline-directed medical therapy pathway once a reduced- or preserved-ejection-fraction cause is confirmed.
Diuretic-refractory ascites out of proportion to peripheral edema — especially with a history of prior cardiac surgery, mediastinal radiation, or recurrent pericarditis — should raise suspicion for constrictive pericarditis. Pursue echocardiography (assessing for respirophasic ventricular interdependence) or cardiac MRI, and refer to cardiology for consideration of pericardiectomy, which can be curative for this specific cause.[5]
Budd-Chiari syndrome (hepatic venous outflow obstruction, often from an underlying myeloproliferative or other prothrombotic disorder) also produces a high-SAAG, high-protein picture that does not fit simple cirrhosis — refer urgently to hepatology for anticoagulation and consideration of interventional (angioplasty/stenting, TIPS) or transplant options.
First-line therapeutic (large-volume) paracentesis for symptom relief — malignant ascites is frequently diuretic-refractory, because the fluid is driven primarily by increased peritoneal capillary permeability and lymphatic obstruction rather than by portal hypertension.[4]
A diuretic trial (spironolactone, adding furosemide if needed) is reasonable specifically when SAAG is ≥ 11 g/L — a "mixed" picture with a portal-hypertensive component, such as extensive hepatic metastatic replacement or coexisting cirrhosis — but response is much less predictable than in cirrhotic ascites, and an isolated low-SAAG carcinomatosis picture typically will not respond meaningfully to diuretics at all.[4]
Recurrent ascites requiring frequent paracentesis (roughly more than once every 1-2 weeks) should prompt referral for placement of an indwelling tunnelled peritoneal catheter, allowing intermittent drainage at home and avoiding repeated procedural visits — a well-established palliative option.[4]
Direct treatment of the underlying malignancy (systemic therapy, where still appropriate) is the only intervention that can durably reduce fluid formation. Involve oncology, and palliative care early, given the poor prognosis malignant ascites generally signals.[4]
Confirmed or strongly suspected tuberculous peritonitis is treated with the standard multidrug antituberculous regimen — isoniazid, rifampin, pyrazinamide, and ethambutol for an intensive phase, followed by a continuation phase, for a total of at least 6 months. The full regimen, phasing, and monitoring schedule are set out in the Tuberculosis chapter and are not repeated here.[3]
Do not wait for AFB culture confirmation — which can take weeks — to start therapy when the ascitic fluid picture (lymphocyte-predominant, elevated ADA) and clinical context are sufficiently suggestive. Refer to infectious disease/public health for case management and contact tracing regardless of confirmation timeline.[3]
Sodium restriction plus a loop diuretic, adding spironolactone if needed, controls fluid in most patients — but diurese more cautiously than the cirrhotic ladder. Patients with nephrotic syndrome are often intravascularly depleted despite total-body fluid overload (from low oncotic pressure), so over-diuresis carries a disproportionate acute kidney injury risk.
Definitive management is treatment of the underlying glomerular disease — corticosteroids or another immunosuppressive regimen, chosen by the specific histologic diagnosis — under nephrology direction. See the current KDIGO glomerular-diseases guideline for the disease-specific immunosuppression pathway, which is outside the scope of this chapter.[6]
Pancreatic ascites results from disruption of the pancreatic duct or a leaking pseudocyst, confirmed by a markedly elevated ascitic fluid amylase. Initial management is bowel rest and octreotide to reduce pancreatic secretion, with endoscopic pancreatic duct stenting or surgery for a persistent leak — manage jointly with gastroenterology and surgery.
Non-Pharmacologic Treatment
- Ultrasound-guided paracentesis reduces complications for both diagnostic and therapeutic taps and should be used routinely; routine correction of mild coagulopathy beforehand is not required.[2]
- Sodium restriction is broadly useful across portal-hypertensive and nephrotic causes (cirrhotic, cardiac, nephrotic) but has limited value as a primary strategy in isolated malignant ascites, where mechanical fluid removal (paracentesis, or a catheter) is the mainstay rather than dietary or diuretic measures.
- Indwelling tunnelled peritoneal catheter for recurrent malignant ascites needing frequent taps — see Choose Initial Treatment.
- Nutrition support for the cachexia that commonly accompanies both malignancy and tuberculous peritonitis; refer to a dietitian early rather than after significant weight loss has already occurred.
- Directly observed therapy adherence support for tuberculous peritonitis, coordinated with the infectious disease/public health team managing the full antituberculous course.
- Definitive treatment of the underlying disease process is the true non-pharmacologic (or procedural) fix in each non-cirrhotic cause: surgical pericardiectomy for constrictive pericarditis, anticoagulation with interventional or transplant options for Budd-Chiari, and endoscopic or surgical duct-leak repair for pancreatic ascites.
- Early psychosocial and palliative care referral for malignant ascites, given the prognosis it generally signals, rather than deferring that conversation until later in the disease course.
Pharmacologic Treatment Options
| Drug / intervention | Role | Dose / use | Important adverse effects | Teaching points |
|---|---|---|---|---|
| Furosemide Preferred | Cardiac and nephrotic-syndrome ascites — first-line loop diuretic | Start 20-40 mg PO once daily; titrate to effect | Hypokalemia, hypovolemia, renal injury with over-diuresis | This is not the cirrhotic 100:40 spironolactone:furosemide ladder described in the Cirrhosis chapter — a different, generally more cautious titration approach applies here. |
| Spironolactone Alternative | Add-on for cardiac or nephrotic-syndrome ascites with an inadequate response to a loop diuretic alone | Start 25-100 mg PO once daily; titrate to effect and serum potassium | Hyperkalemia, gynecomastia | In nephrotic syndrome, watch potassium closely — intravascular depletion from aggressive combination diuresis carries a real acute kidney injury risk (see Special Populations). |
| Isoniazid + rifampin + pyrazinamide + ethambutol Preferred | Confirmed or strongly suspected tuberculous peritonitis — standard 4-drug regimen | Weight-based dosing, minimum 6-month total duration — see the Tuberculosis chapter for the complete regimen, phasing, and monitoring schedule | Hepatotoxicity (all 4, pyrazinamide most), optic neuritis (ethambutol), peripheral neuropathy (isoniazid) | Do not wait for AFB culture confirmation to start therapy when the fluid picture and clinical context are sufficiently suggestive. |
| Octreotide Special situation | Pancreatic (or biliary) ascites — reduces pancreatic ductal secretion while a duct leak is addressed | 100-200 mcg SC 3 times daily (specialist-initiated); a continuous IV infusion is an alternative in the acute inpatient setting | GI upset, hyperglycemia, cholelithiasis with prolonged use | Adjunct to bowel rest and definitive duct-leak management (endoscopic stenting or surgery) — not a stand-alone therapy. |
| Prednisone (or another immunosuppressive agent) Special situation | Nephrotic-syndrome ascites — definitive therapy directed at the underlying glomerular disease | Agent and regimen chosen by nephrology based on the specific histologic diagnosis — not a fixed platform-wide dose | Depends on the agent and duration selected | Diuretics only control the fluid; treating the glomerular disease itself is what durably resolves it — see the current KDIGO glomerular-diseases guideline. |
Special Populations
Pregnancy
True ascites in pregnancy is uncommon but can occur with ovarian hyperstimulation syndrome (in the context of fertility treatment) or with the capillary-leak physiology of severe preeclampsia — see the Preeclampsia chapter for that specific work-up and management. Distinguish genuine ascites from the physiologic abdominal changes of pregnancy on exam and, where needed, with ultrasound.
Pediatrics
Nephrotic syndrome (particularly minimal change disease) is a relatively more common cause of ascites in children than in adults. Tuberculous peritonitis risk follows regional epidemiology, and malignancy is a less common but still important consideration; the same SAAG-directed work-up applies, adapted to pediatric reference ranges and weight-based dosing.
Older adults
New ascites in an older adult carries a higher baseline pretest probability of an occult malignancy as the cause — a lower threshold for cytology and CT staging as part of the initial work-up is reasonable rather than assuming a benign or age-related explanation.
Mixed / dual-pathology ascites
A patient can have more than one concurrent driver — most importantly a patient with known cirrhosis who develops a second, superimposed process such as peritoneal carcinomatosis or heart failure. This can produce an indeterminate SAAG/total-protein pattern that does not cleanly fit either category. Do not force a single-cause interpretation when the clinical picture, treatment response, or fluid studies don't fit — repeat paracentesis with additional studies (cytology, ADA) if response to cause-directed therapy is atypical (see Treatment Failure / Next Step).
Immunocompromised patients
HIV infection, transplant recipients, and patients on biologic or other immunosuppressive therapy have a substantially higher pretest probability of tuberculous peritonitis than the general population — maintain a lower threshold for ADA and AFB testing on the initial ascitic fluid panel in this group.
Peritoneal dialysis patients
Distinguish a dialysis-related complication (peritonitis from a PD catheter infection, affecting the dialysate rather than a separate ascitic collection) from true new-onset ascites in a PD patient — a different diagnostic and management context, outside the scope of this chapter. Refer to the treating nephrology/PD team.
Monitoring & Follow-Up
- After a diagnostic paracentesis, actively track culture, cytology, and ADA results and close the loop with the ordering clinician — diagnostic uncertainty should not be left open once results are available.
- Cardiac ascites: daily weights during diuretic titration, renal function and electrolytes, and heart-failure-specific monitoring per the Heart Failure chapter.
- Malignant ascites: track the frequency and volume of paracenteses needed — a shortening interval between taps is the trigger for catheter referral (see Treatment Failure / Next Step); coordinate with oncology on staging and treatment response.
- Tuberculous peritonitis: standard antituberculous monitoring (baseline and monthly liver enzymes, monthly visual acuity/colour vision on ethambutol, uric acid on pyrazinamide, and directly-observed-therapy adherence tracking) per the Tuberculosis chapter.
- Nephrotic-syndrome ascites: proteinuria trend, renal function, and immunosuppression-specific monitoring per nephrology-directed follow-up.[6]
- For confirmed cirrhotic ascites, follow the monitoring schedule in the Cirrhosis chapter rather than a separate schedule here.
- Reassess the diagnosis, not just the treatment, whenever the response is atypical for the presumed cause — see Treatment Failure / Next Step.
Treatment Failure / Next Step
- Ascites recurring rapidly despite an appropriate cause-directed regimen — reconfirm the diagnosis with a repeat paracentesis and a fuller panel (cytology, ADA, culture) rather than assuming simple treatment failure of the original diagnosis.
- Suspected cardiac ascites not responding to diuretics — reassess for constrictive pericarditis (see Choose Initial Treatment) and confirm heart-failure therapy is optimized per the Heart Failure chapter before escalating the diuretic dose further.[5]
- Malignant ascites needing paracentesis more than roughly every 1-2 weeks — refer for an indwelling peritoneal catheter rather than continuing serial large-volume taps indefinitely.[4]
- A previously stable cirrhotic patient whose ascites pattern changes (faster reaccumulation, new systemic symptoms, bloody fluid) — repeat paracentesis with cytology to exclude a second, superimposed cause (e.g., peritoneal carcinomatosis) rather than assuming simple progression of the known cirrhosis (see Special Populations).
- Tuberculous peritonitis not improving on appropriate multidrug therapy — reassess adherence (directly observed therapy) and drug susceptibility per the Tuberculosis chapter before concluding treatment has failed.[3]
- Nephrotic-syndrome ascites persisting or worsening despite diuretics and immunosuppression — nephrology reassessment for an alternative or resistant histologic diagnosis.[6]
- New fever, abdominal pain, or worsening renal function/encephalopathy in any patient with ascites during treatment — this is the SBP presentation; work up and manage per the Cirrhosis chapter's SBP content regardless of the ascites etiology.[2]
Common Errors to Avoid
- Assuming all ascites is cirrhotic and skipping diagnostic paracentesis because the cause "looks obvious" — the SAAG-directed work-up changes management often enough that it should never be skipped at first presentation.[2]
- Using SAAG in isolation without total protein and the rest of the fluid panel, especially when the picture doesn't fit cleanly (see Assessment & Diagnosis and Special Populations for mixed/dual-pathology ascites).
- Applying the cirrhotic diuretic ladder by default to malignant ascites — isolated peritoneal carcinomatosis is frequently diuretic-refractory, and reflexively trialing diuretics first delays the therapy (paracentesis, an indwelling catheter) that actually helps.[4]
- Missing tuberculous peritonitis by not sending adenosine deaminase/AFB studies in a patient with relevant risk factors, because the presentation can closely mimic malignant ascites.[3]
- Missing nephrotic-syndrome ascites by not checking urinalysis/proteinuria in a patient with edema and ascites but normal liver enzymes and imaging.
- Over-diuresing nephrotic-syndrome ascites — total-body fluid overload can coexist with intravascular depletion, so aggressive diuresis carries a disproportionate acute kidney injury risk.
- Missing a second, superimposed cause in a patient with known cirrhosis whose ascites pattern changes — see Treatment Failure / Next Step.
- Re-deriving or restating the cirrhotic-specific management ladder here instead of directing to the Cirrhosis chapter — kept out deliberately so the two chapters don't drift out of sync with each other over time.
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
The cirrhotic-specific spironolactone/furosemide 100:40 titration ladder, its maximum doses, and its refractory-ascites definitions are covered in the Cirrhosis chapter's drug tables and are not repeated here. The tables below cover diuresis for the non-cirrhotic, non-portal-hypertensive-mechanism causes and the etiology-directed therapies specific to this chapter.
Diuretics for cardiac and nephrotic-syndrome ascites
Titrate more cautiously than the cirrhotic ladder — both cardiac and nephrotic-syndrome ascites carry a distinct over-diuresis/renal-injury risk profile from cirrhotic ascites.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Furosemide | Starting dose: 20-40 mg PO once daily Titration: Titrate to effect and daily weight; more cautiously in nephrotic syndrome given intravascular-depletion risk | Hypokalemia, hypovolemia, ototoxicity at high doses, renal injury with over-diuresis | Additive nephrotoxicity with NSAIDs/aminoglycosides; reduced effect with concurrent NSAID use | First-line loop diuretic for cardiac and nephrotic-syndrome ascites; add spironolactone if response is inadequate.[2] |
| Spironolactone | Starting dose: 25-100 mg PO once daily Titration: Titrate to effect and serum potassium | Hyperkalemia, gynecomastia and breast tenderness (dose-related), GI upset | Additive hyperkalemia with ACE inhibitors/ARBs/potassium supplements; reduces digoxin clearance | Add-on when a loop diuretic alone is insufficient; watch potassium closely, particularly in nephrotic syndrome.[2] |
Pancreatic/biliary ascites
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Octreotide | Subcutaneous: 100-200 mcg SC 3 times daily, specialist-initiated Continuous IV: An alternative in the acute inpatient setting | GI upset, hyperglycemia, cholelithiasis with prolonged use, bradycardia | May alter insulin/oral hypoglycemic requirements | Reduces pancreatic ductal secretion while a duct leak is definitively addressed (endoscopic stenting or surgery) — an adjunct, not a stand-alone therapy. |
Tuberculous peritonitis
The complete 4-drug regimen, weight-based dosing, phasing (intensive/continuation), and monitoring schedule are in the Tuberculosis chapter's drug tables — summarized here only to flag the class and minimum duration.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Isoniazid | —: See the Tuberculosis chapter for weight-based dosing | Hepatotoxicity, peripheral neuropathy (dose-related) | Numerous — review the full medication list before starting; give pyridoxine in patients at neuropathy risk | 1 of 4 first-line agents; minimum 6-month total treatment duration for tuberculous peritonitis.[3] |
| Rifampin | —: See the Tuberculosis chapter for weight-based dosing | Hepatotoxicity, orange discoloration of body fluids, GI upset | Extensive CYP-mediated drug interactions | 1 of 4 first-line agents.[3] |
| Pyrazinamide | —: See the Tuberculosis chapter for weight-based dosing | Hepatotoxicity (most hepatotoxic of the 4 first-line drugs), hyperuricemia/arthralgia | None clinically significant at standard dosing | 1 of 4 first-line agents, intensive phase.[3] |
| Ethambutol | —: See the Tuberculosis chapter for weight-based dosing | Dose-related optic neuritis — decreased visual acuity, red-green colour blindness | None clinically significant at standard dosing | 1 of 4 first-line agents, intensive phase; baseline and monthly visual acuity/colour vision testing.[3] |
Nephrotic-syndrome ascites — immunosuppression
Diuretics (above) control the fluid; only treating the glomerular disease itself durably resolves it. Agent, dose, and duration are chosen by nephrology based on the specific histologic diagnosis — this is not a fixed platform-wide regimen.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Prednisone (or another immunosuppressive agent) | —: Nephrology-directed — not a fixed dose | Hyperglycemia, hypertension, mood/sleep disturbance, infection risk, osteoporosis with prolonged use | Numerous — review the full medication list; additive hyperglycemia with other agents | Regimen individualized by nephrology per the underlying histologic diagnosis — see the current KDIGO glomerular-diseases guideline.[6] |
A general caution across ascites of any etiology
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| NSAIDs (e.g., ibuprofen, naproxen) | —: Avoid where an alternative analgesic exists | Sodium and fluid retention that counteracts diuretic therapy; renal injury risk, particularly with concurrent diuretic use | Reduces diuretic efficacy; additive nephrotoxicity with other nephrotoxic agents | Promotes sodium and water retention in any edematous or ascitic state — cardiac and nephrotic-syndrome ascites included, not only the renal-perfusion-dependence reasoning specific to portal hypertension described in the Cirrhosis chapter. |
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.